An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00302380
First received: March 10, 2006
Last updated: June 27, 2011
Last verified: June 2011
  Purpose

The primary objective of this study is to evaluate the Binding Potential in subjects with ADHD and adults without ADHD: the intent being to demonstrate that C-11 Altropane PET can be used to differentiate adults with ADHD from healthy control subjects.


Condition Intervention Phase
Attention Deficit Hyperactivity Disorder
Radiation: PET imaging using C-11 altropane as the ligand.
Phase 1
Phase 2

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • The DAT receptor occupancy of OROS MPH and Metadate CD in adults with and without ADHD using PET scanning with C-11 Altropane. [ Time Frame: Subjects will lie still in the PET camera for a 90 minute period. ] [ Designated as safety issue: No ]
    PET imaging will be acquired using either a HR+ or Siemens Biograph 64 PET/CT camera.


Secondary Outcome Measures:
  • Neuropsychological tests [ Time Frame: Examination of cognitive-neuropsychological functioning will take approximately 2.5 hours to complete. ] [ Designated as safety issue: No ]
    Cognitive-neuropsychological functioning will be examined by selected tests that are thought to reflect basic deficits in ADHD, mainly those believed to measure components of attention and prefrontal brain systems.

  • Genotyping [ Time Frame: A sample of blood (2 tablespoons) will be drawn from all subjects. ] [ Designated as safety issue: No ]
    Genotyping will be performed using a custom markers for dopamine-related genes (DAT, DRD4-7, D2, and DBH).


Biospecimen Retention:   Samples With DNA

A sample of blood (2 tablespoons) will be drawn from all subjects.


Enrollment: 300
Study Start Date: October 2000
Study Completion Date: March 2006
Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
un-medicated subjects with ADHD Radiation: PET imaging using C-11 altropane as the ligand.
A one-injection protocol will be used for the study. C-11 Altropane will be injected manually as an intravenous bolus.
subjects without ADHD Radiation: PET imaging using C-11 altropane as the ligand.
A one-injection protocol will be used for the study. C-11 Altropane will be injected manually as an intravenous bolus.

Detailed Description:

This protocol seeks to replicate and extend our investigation of DAT binding in adults with ADHD with specific aims:

  1. To examine dopamine transporter (DAT) receptor binding potential in adults with ADHD, using PET scanning with 11C altropane as the ligand. We hypothesize that compared to adults without ADHD, adults with ADHD will have greater DAT binding that will not be accounted by psychiatric comorbidity or age.
  2. To examine the relationship of DAT binding to clinical features of ADHD. We hypothesize that DAT binding will be positively correlated with a) severity of ADHD symptoms and b) neuropsychological and interpersonal dysfunction.
  3. To examine the relationship between DAT binding and genetic risk factors. We hypothesize that DAT binding will be specifically associated with homozygosity of the DAT (480) gene in adults with ADHD and not with other ADHD-associated genetic markers (e.g., DRD4-7, D2, DBH).
  Eligibility

Ages Eligible for Study:   18 Months to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

200 un-medicated subjects with ADHD and 100 subjects without ADHD will be recruited sequentially. No individual will be excluded based on gender, race, or ethnicity.

Criteria

Inclusion Criteria:

  1. Signed written informed consent to participate in the study.
  2. Age: 18 - 55
  3. If female, non-pregnant, non-nursing with a negative serum pregnancy test and using an adequate form of birth control.
  4. Supine and standing blood pressure within the range 110/60 to 150/90 mmHg.
  5. Heart rate, after resting for 5 minutes, within the range 46-90 beats/min.
  6. Subjects who are within 20% of the ideal weight for height
  7. Right handed
  8. Diagnosis of DSM-IV ADHD (current), as manifested in clinical evaluation and confirmed by structured interview (for ADHD study subjects).
  9. Subjects without a diagnosis of DSM-IV ADHD (lifetime), as manifested in clinical evaluation and confirmed by structured interview (for control study subjects).

Exclusion Criteria:

  1. Diagnosis of any psychotic disorder, bipolar disorder, severe depression, severe anxiety, or Autism. Subjects with mild mood, oppositional, conduct, and anxiety disorders may be permitted to participate if considered appropriate by the investigator
  2. Scores of Baseline Scales:

    Hamilton Depression Scale > 17 (out of a possible 67 on the 21-item scale)(Hamilton 1960) Beck Depression Inventory > 19 (out of a possible 63 on the 21-item scale)(Beck, Ward et al. 1961) Hamilton Anxiety Scale > 21 (out of a possible 56 on the 14-item scale)(Hamilton 1959)

  3. History of head trauma with loss of consciousness, organic brain disorders, seizures, or neurosurgical intervention.
  4. Any clinically significant chronic medical condition, in the judgement of the investigator.
  5. Mental impairment as evidenced by an I.Q. <75.
  6. Subject must be off any investigational drug for at least 4 weeks prior to the start of the study.
  7. Exposure to dopamine receptor antagonists, including stimulant medications (e.g. methylphenidate) or buproprion within the previous three (3) months to the start of the study.
  8. Exposure to non-stimulant ADHD medications (e.g. atomoxetine) within the previous 4 weeks to the start of the study.
  9. Exposure to radiopharmaceuticals within four (4) weeks prior to PET scan.
  10. Subjects receiving psychotropic medication.
  11. Any clinically significant abnormality in the screening laboratory tests, vital signs, or 12-lead ECG, outside of normal limits.
  12. Any woman of childbearing potential who is seeking to become pregnant or suspects that she may be pregnant.
  13. Subjects with a known recent history (within the past six (6) months) of illicit drug or alcohol dependence.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00302380

Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: Thomas Spencer, MD Massachusetts General Hospital
  More Information

No publications provided by Massachusetts General Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Thomas Spencer, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00302380     History of Changes
Other Study ID Numbers: 2000-p-001975
Study First Received: March 10, 2006
Last Updated: June 27, 2011
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders Diagnosed in Childhood
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Dopamine
Cardiotonic Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents

ClinicalTrials.gov processed this record on July 24, 2014